H.C. Wainwright raised the firm’s price target on Ultragenyx (RARE) to $95 from $82 and keeps a Buy rating on the shares post the Q3 report. The firm believes the company’s path to profitability in 2026 is achievable.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter